Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.00%
)
US TECH 100
23,240.80
(
-1.16%
)
Dow Jones
46,429.49
(
0.00%
)
Brent Oil
102.55
(
3.82%
)
Bitcoin
69,396.55
(
-2.68%
)
News Focus
News Focus
Post# of 257288
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 104035

Monday, 02/28/2011 2:01:46 AM

Monday, February 28, 2011 2:01:46 AM

Post# of 257288
Pharming/SNTS get FDA Refusal-to-File letter for Rhucin in HAE:

http://finance.yahoo.com/news/Santarus-and-Pharming-bw-1473998633.html?x=0&.v=1

Inasmuch as the FDA is requiring results of a phase-3b trial as a condition for resubmission of the BLA, it’s reasonable to infer that the companies knew of the pending rejection when they announced the start of the phase-3b trial a few days ago (http://finance.yahoo.com/news/Santarus-and-Pharming-bw-1313301398.html?x=0&.v=1 ).

Pharming and SNTS inked a deal to co-develop Rhucin for the US market in Sep 2010 (#msg-54323285).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up